Phaseline

Targets › UBE3A

UBE3A (Ubiquitin-protein ligase E3A): drug programs, companies and trials

4 programs from 4 companies in 8 trials: 5 Phase 3, 2 Phase 1, 1 Phase 2; Other; next expected readout Aug 2027.

E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and transfers it to its substrates. Several substrates have been identified including the BMAL1, ARC, LAMTOR1, RAD23A and RAD23B, MCM7 (which is involved in DNA replication), annexin A1, the PML tumor suppressor, and the cell cycle regulator CDKN1B. Additionally, may function as a cellular quality…. (UniProt, Q05086)

Open in Phaseline: the race on UBE3A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ionis Pharmaceuticalsobudanersen (ION582)
antisense oligonucleotide targeting paternal UBE3A mRNA to restore maternal UBE3A expressi
UBE3APhase 3Angelman SyndromeAug 2027
OHB Pediatricsrugonersen
UBE3A antisense oligonucleotide
UBE3APhase 3Angelman SyndromeMar 2029
Ultragenyx PharmaceuticalGTX-102 (apazunersen)
Antisense oligonucleotide targeting UBE3A
UBE3APhase 3Angelman Syndrome–
MavriX BioMVX-220
AAVhu68 viral vector delivering UBE3A gene
UBE3APhase 1Angelman SyndromeMar 2028

Conditions

Angelman Syndrome (8)

Modalities

other (4)

Companies

MavriX Bio (1) Ionis Pharmaceuticals (1) OHB Pediatrics (1) Ultragenyx Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.